Update shared on 15 Nov 2025
Analysts have modestly adjusted their price target for Simulations Plus from $23.00 to $23.00. They cite subtle changes in assumptions around discount rate and profit margins, while maintaining steady core growth expectations.
What's in the News
- Simulations Plus provided preliminary earnings guidance for fiscal year 2025, projecting revenue of $79 million with growth of approximately 13% (Key Developments)
- The company updated its earnings guidance for fiscal year 2026, now expecting revenue between $79 million and $82 million, with revenue growth anticipated at 0% to 4% (Key Developments)
- Simulations Plus was dropped from the S&P 600 Health Care Sector (Key Developments)
- The company was also removed from the S&P 1000, S&P Composite 1500, and S&P 600 indexes (Key Developments)
Valuation Changes
- Consensus Analyst Price Target remains unchanged at $23.00 per share.
- Discount Rate has risen slightly from 7.89% to 8.14%.
- Revenue Growth projection is virtually unchanged, holding at 5.71%.
- Net Profit Margin remains steady at 12.41%.
- Future P/E has increased marginally from 49.02x to 49.36x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.